{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-013281","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.156173+00:00","generated_at":"2026-06-19T07:33:02.495663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmuCell reports net loss of $2.5M for 2022; second contamination event slows Q1 2023 production","bullets":["Net loss of $2.5M ($0.32 per share) vs loss of $78k in 2021; gross margin fell to 41% from 45%.","EBITDA dropped to $350k from $2.7M; cash decreased to $5.8M from $10.2M.","Second contamination event detected in Q1 2023; production slowdown and backlog more than doubled since year-end.","Deferred planned capacity expansion to over $40M/year due to lost gross margin in Q1 2023.","Aiming to re-submit CMC Technical Section for Re-Tain to FDA in Q1 2023, subject to external lab results."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-013281","json":"https://secwatch.observer/filing/0001213900-23-013281.json","markdown":"https://secwatch.observer/filing/0001213900-23-013281.md","text":"https://secwatch.observer/filing/0001213900-23-013281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023013281/0001213900-23-013281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023013281/ea174041-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:33:02.495663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a7b31a41b0f44cd151dc9a1bb6fe46a81d20b47","claim":"IMMUCELL CORP /DE/ reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On February 21, 2023 ImmuCell Corporation (the \"Company\") issued a press release announcing the unaudited financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023013281/0001213900-23-013281-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}